Managing tardive dyskinesia (TD) requires a precise pharmacological approach to balance psychiatric stability and motor control. Recent research highlights that using VMAT2 inhibitors for TD offers significant advantages over traditional anticholinergic medications. Traditionally, clinicians used anticholinergics for drug-induced movement disorders. However, evidence now shows these drugs may worsen TD symptoms rather than provide relief. Consequently, the medical community is shifting toward more selective treatments like valbenazine and deutetrabenazine.

Research Insights: VMAT2 Inhibitors for TD

A study by Hsu TW et al. recently addressed the safety profiles of different TD treatments through target trial emulation. This advanced research method mimics a randomized controlled trial using real-world data. Specifically, the authors emphasized the importance of "time zero alignment." By ensuring that follow-up starts exactly when treatment begins, researchers can avoid immortal time bias. The findings demonstrate that VMAT2 inhibitors lead to fewer adverse outcomes than anticholinergics. Moreover, these selective agents provide more consistent control of involuntary movements. Therefore, VMAT2 inhibitors represent a safer and more reliable therapeutic choice for modern practice.

Clinical Superiority and Guidelines

Current clinical guidelines now identify VMAT2 inhibitors as the first-line treatment for moderate to severe TD. Unlike anticholinergics, which target acetylcholine receptors, VMAT2 inhibitors deplete presynaptic dopamine. This mechanism directly addresses the pathophysiology of dopamine supersensitivity. Furthermore, VMAT2 inhibitors avoid the cognitive decline and dry mouth common with anticholinergic use. In contrast, anticholinergics are only recommended for acute extrapyramidal side effects, not for TD. Consequently, practitioners must differentiate between these movement disorders to ensure patients receive the correct intervention.

Frequently Asked Questions

How does target trial emulation improve TD research?

Target trial emulation allows researchers to structure observational studies like clinical trials. By using techniques like time zero alignment, it removes common biases that occur when comparing drugs with different initiation times. This provides more accurate safety and efficacy data for clinicians.

Can anticholinergics be used for tardive dyskinesia?

Generally, medical experts discourage using anticholinergics for TD. While they help with acute parkinsonism, they can mask TD symptoms or even exacerbate the underlying involuntary movements. Transitioning to VMAT2 inhibitors is the current standard of care.

Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Hsu TW et al. Response to [Time zero alignment in target trial emulation of VMAT2 inhibitors versus anticholinergics for tardive dyskinesia]. Psychiatry Clin Neurosci. 2026 Jun 17. doi: 10.1111/pcn.70095. PMID: 42308002.

Keepers GA et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177(9):868-872.

Tarsy D. Treatment of tardive dyskinesia. UpToDate. Accessed June 2026.